Baseline characteristics (age, gender, number of metastatic locations, CEA, and CA 19–9 levels and K-ras mutation status) and treatment details such as number of cycles, resection status of the primary tumour, type of chemotherapeutic agent combined with bevacizumab, and response to treatment of all patients are represented in Tables 1 and 2. Here, KRAS is linked to neoplasm.